Skip to main content
. Author manuscript; available in PMC: 2021 Aug 4.
Published in final edited form as: Circulation. 2020 May 1;142(5):483–498. doi: 10.1161/CIRCULATIONAHA.119.044803

Figure 1. TFEB is downregulated in human and mouse aortic aneurysm.

Figure 1.

(A) Transcription factor EB (TFEB) mRNA and (B) protein were determined by quantitative polymerase chain reaction (qPCR) and Western blot, respectively, in human proximal ascending aortic aneurysm lesions compared with that in the adjacent normal aorta (n=12 for mRNA, n=8 for protein). (C) TFEB was detected by immunofluorescence in human aneurysmal lesions and adjacent normal aorta. Scale bar, 50 μm. (D) Human aortic smooth muscle cells (HASMCs) were treated with tumor necrosis factor α (TNFα; 20 ng/mL), interleukin 1 β (IL1β; 10 ng/mL) or Interferon γ (IFNγ; 50 ng/mL) for 72 hours. TFEB protein was determined by Western blot (n=3). (E-F) In the proprotein convertase subtilisin/kexin type 9 (PCSK9)/ angiotensin II (AngII) model, TFEB mRNA and protein were determined in the aortas of AngII- and saline-infused mice by qPCR (E; n=15 for saline, n=8 for AngII) or Western blot (F; n=6). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. Paired t-test for A and B, one-way ANOVA followed by Holm-Sidak post hoc analysis for D, and unpaired t-test for E and F.